Researcher Spotlight: Jordan Goldstein, MD STANFORD UNIVERSITY Errol M. Cook Memorial Scholar Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma, with many patients experiencing relapse after first-line therapy. Many patients now receive treatment with a chimeric…
Researcher Spotlight: Adam DuVall, MD UNIVERSITY OF CHICAGO Chike Springer Foundation Scholar Adolescents and young adults with cancers such as lymphoma have unique emotional and psychosocial needs as a result of their disease and treatment. While survival outcomes rates are…
Researcher Spotlight: Moah Soan, DVM, PhD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Jaime Peykoff Follicular Lymphoma Fellow Breakthrough therapies such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies have transformed the care of patients with follicular lymphoma…
Researcher Spotlight: Vignesh Shanmugam, MD BRIGHAM AND WOMEN’S HOSPITAL, INC. Tom Condon Family Fellow In many types of lymphoma, such as follicular lymphoma (FL), tumor cells are embedded in a rich microenvironment of non-malignant cells with which they regularly interact.…
Researcher Spotlight: Michael Schneider, MD, PhD THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Treatment of lymphoma has been revolutionized by the development of chimeric antigen receptor (CAR) T-cell therapies, which elicit robust responses in many patients. However, a large number…
Researcher Spotlight: Benedikt Pelzer, MD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY The Levine Family Fellowship Marginal zone lymphoma (MZL) is a slow-growing type of cancer that can eventually transform into a more aggressive diffuse B-cell lymphoma (DLBCL) in a subset…
Researcher Spotlight: Atish Kizhakeyil, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Alterations in the DTX1 gene are highly prevalent in diffuse large B-cell lymphoma (DLBCL), but their clinical significance remains unclear. Using animal models and advanced genomic technologies, Dr.…
Researcher Spotlight: Alberto Carturan, MD UNIVERSITY OF PENNSYLVANIA Jaime Peykoff Follicular Lymphoma Fellow Chimeric antigen receptor (CAR) T-cell therapies represent a groundbreaking advancement in the treatment of lymphoma. While CAR T-cell therapies have produced remarkable results for many patients, these…
Researcher Spotlight: Gonzalo Blanco Ares, PhD THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH Bruce D. Cheson, MD Fellow Care of patients with chronic lymphocytic leukemia (CLL) is complicated by the immunodeficiency that is associated with the disease, which can lead to…
Researcher Spotlight: Samuel Yamshon, MD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY The lymphoma treatment landscape has been dramatically changed in recent years with the development of novel immunotherapies such as chimeric antigen receptor (CAR) T cells and bispecific antibodies. Dr.…
